Recent Bans and Stricter Reviews on Dietary Supplement Ingredients in Overseas Markets

Since 2026, regulatory pressure on health supplement ingredients has intensified across major global markets. From the EU’s tightening of its “other substances” review list, to the U.S. FDA’s strengthened oversight of dietary supplements, and reclassification of specific ingredients in the UK and Australia – the signal is clear: compliance barriers are rising fast. This article summarizes recent overseas bans and tightened controls on supplement ingredients for the reference of private label clients and industry peers.

1. Europe – Three Focus Areas: Red Yeast Rice, Garcinia Cambogia, CBD

(A) EU to ban Monacolin K from red yeast rice

In 2026, the EU officially accepted EFSA’s risk assessment on Monacolin K from red yeast rice, moving to add it to Annex III, Part A of Regulation (EC) No 1925/2006 (list of prohibited substances). The ban is expected to take effect in Q3 2026. EFSA concluded that as low as 3 mg/day of Monacolin K can cause serious adverse effects including rhabdomyolysis and liver injury, and industry submissions failed to demonstrate a safe intake level. The ban applies only to Monacolin K from red yeast rice; red yeast rice without Monacolin K can still be sold in the EU.

(B) France extends ban on Garcinia cambogia supplements until April 2027

On 17 April 2026, France issued an order extending the suspension on import, marketing, and sale of supplements containing Garcinia cambogia for another year, until 18 April 2027. ANSES (French food safety agency) cited potential acute health risks from hydroxycitric acid, the main active component. The ban will remain until an EU‑level risk assessment is completed.

(C) CBD multiple restrictions – food ban imminent

• EFSA safety update (Feb 2026): temporary acceptable daily intake set at 0.0275 mg/kg body weight/day (approx. 2 mg/day for a 70 kg adult). This effectively outlaws high‑dose CBD food supplements, though very low doses remain nominally possible.

• ECHA (March 2026): proposed to classify CBD as a reproductive toxicant. Cosmetics and food supplements containing CBD must update safety data sheets and labels immediately.

• SCCS final opinion (April 2026): CBD in cosmetic products is safe up to 0.19% concentration, with THC impurity ≤0.00025%.

• France (effective 15 May 2026): all food‑type products containing CBD (including oils, teas, candies) are banned from sale in France, because CBD has never been authorised as a novel food.

(D) EU tightens import controls on Chinese ARA oil

On 24 February 2026, the EU adopted Regulation (EU) 2026/459 imposing official controls and emergency measures on arachidonic acid oil (ARA) from China, due to Bacillus cereus toxin risks. Each batch is subject to 50% physical checks and must test “not detected” for toxins. Effective 26 February 2026.

2. United States – Stronger FDA enforcement and legislative reform

Enhanced enforcement & import controls
On 24 April 2026, the FDA announced further clarification of NDI notification requirements and continued cGMP inspections of dietary supplement facilities, including unannounced audits of overseas manufacturers. On 20 April 2026, FDA issued Import Alert 99‑45 – allowing DWPE (detention without physical examination) for food products (including supplements) containing unsafe food additives. In April 2026, the FDA warned consumers not to consume or distribute Addall XR Shot or Addall XL.

Legislative reform – Premarket authorization bills

• H.R. 7366 (Dietary Supplement Regulatory Uniformity Act, 13 Feb 2026): clarifies FDA’s exclusive jurisdiction over dietary supplements, blocking state‑level divergent standards.

• H.R. 8370 (Dietary Supplement Listing Act, 20 April 2026): requires every dietary supplement sold in the U.S. to be listed with the FDA. Existing products must be listed within 18 months (starting 1 Jan 2027); new products must be listed before marketing. Companies must provide full supply chain information within 5 calendar days of an FDA request, including all manufacturing, packaging and labelling addresses and all raw material suppliers. The Natural Products Association (NPA) strongly opposes the bill, citing potential unnecessary litigation and compliance burden.

3. United Kingdom – Melatonin clampdown (illegal online ads)

In the UK, melatonin is a prescription‑only medicine; any non‑prescription sale is illegal. A February 2026 investigation by Which? found a surge of illegal melatonin ads on AliExpress, Amazon, eBay, Etsy, Superdrug Marketplace and Temu between October 2025 and January 2026. Some products claimed doses up to 30 mg – 15 times the NHS starting dose. Sellers used variant spellings and hidden ingredients to bypass monitoring. Which? called for stronger government enforcement on supplement platforms.

4. Australia – TGA reclassifies multiple ingredients (B6 restricted, melatonin only via prescription)

In Australia, melatonin is generally available only as a prescription medicine (Schedule 4); limited non‑prescription (Schedule 3) access is allowed for specific conditions (e.g., jet lag for certain age groups).

In 2026, TGA continues modernising medicine regulations. Vitamin B6 is a key target:

• From June 2027, supplements with 50–200 mg/day B6 will move to Schedule 3 (pharmacist only).

• Products with >200 mg/day remain prescription‑only.

• Low‑dose products (<50 mg/day) stay general retail.

• This follows 208 reported adverse events linked to B6‑related neuropathy (including 130 in the first ten months of 2025 alone).

5. South Korea – MFDS cracks down on AI‑generated false ads

Korea’s MFDS is ramping up supervision of AI‑generated deceptive advertising in 2026. Previously it caught cases using AI‑generated doctor avatars to claim, e.g., that NMN supplements reduce grey hair by 178%. MFDS announced it will further tighten monitoring of AI‑generated expert endorsements.

Key Takeaways for Supplement OEM/Private Label Clients

With global regulatory tightening, consider the following:

• Establish real‑time tracking of regulations in export target countries, especially FDA’s NDI rules, EU novel food regulations, and local reclassifications.

• Prioritise ingredients already listed under novel food approvals. Avoid ingredients facing bans/reclassification (e.g., Monacolin K from red yeast rice, high‑dose CBD).

• For the US market, monitor H.R. 8370 closely. Prepare full batch testing, supply chain documentation, and quality system certifications to meet potential 5‑day response deadlines. Large brands should consider working with contract manufacturers holding ISO 22000 and cGMP certifications.

• For Europe, be aware of origin‑specific emergency control measures (e.g., ARA oil from China). Strengthen compliance of contaminant testing reports at source.

• For countries with differentiated rules (e.g., South Korea, UK), pay special attention to influencer marketing and AI‑generated advertising claims – ensure all claims are truthful and substantiated.

• Strictly follow GMP: from 2026, Amazon requires all dietary supplement sellers to pass third‑party testing proving cGMP compliance – quality control is now a marketplace access threshold.

*As a source manufacturer with 18 years of experience, we provide fully customizable OEM/ODM solutions in softgels, hard capsules, tablets, and powders, with end‑to‑end quality control. We can help formulate compliant products tailored to the regulatory landscapes of different countries.*

Disclaimer: This article is a summary of publicly available regulatory information and does not constitute legal or compliance advice. For binding requirements in your target export market, please consult a local licensed attorney or compliance specialist.